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Abstract
The World Health Organization has clearly indentified prevention and early detection as major
objectives in the control of the oral cancer burden worldwide. At the present time, screening of
oral cancer and its pre-invasive intra-epithelial stages, as well as its early detection, is still largely
based on visual examination of the mouth. There is strong available evidence to suggest that visual
inspection of the oral mucosa is effective in reducing mortality from oral cancer in individuals
exposed to risk factors. Simple visual examination, however, is well known to be limited by
subjective interpretation and by the potential, albeit rare, occurrence of dysplasia and early OSCC
within areas of normal-looking oral mucosa. As a consequence, adjunctive techniques have been
suggested to increase our ability to differentiate between benign abnormalities and dysplastic/
malignant changes as well as to identify areas of dysplasia/early OSCC that are not visible to naked
eye. These include the use of toluidine blue, brush biopsy, chemiluminescence and tissue
autofluorescence. The present paper reviews the evidence supporting the efficacy of the
aforementioned techniques in improving the identification of dysplastic/malignant changes of the
oral mucosa. We conclude that available studies have shown promising results, but strong evidence
to support the use of oral cancer diagnostic aids is still lacking. Further research with clear
objectives, well-defined population cohorts, and sound methodology is strongly required.
Introduction
Cancer of the head and neck (H&N cancer), including all
oral, laryngeal and pharyngeal sites, is the sixth most com-
mon cancer, accounting for about 643 000 new cases
annually [1]. About 40% of head and neck malignancies
are known to be squamous cell carcinomas arising in the
oral cavity [2]. Oral cancer is largely related to lifestyle,
with major risk factors being tobacco and alcohol misuse.
In addition to smoking, the use of smokeless tobacco has
been strongly linked to oral cancer [2].
Five-year survival of oral cancer varies from 81% for
patients with localized disease to 42% for those with
regional disease and to 17% if distant metastases are
present [3]. Generally, according to late-stage diagnosis,
fewer than 50% of patients with oral and pharyngeal can-
cers survive more than 5 years. This rate has remained dis-
appointingly low and relatively constant during the last
few decades [2-4].
Treatment of oral cancer often produces dysfunction and
distortions in speech, mastication and swallowing, and
dental health. It can also affect the patient's ability to
interact socially, hence it must be considered among the
most debilitating and disfiguring of all cancers [4-6].
It is well established that virtually all oral squamous cell
carcinomas (OSCCs) are preceded by visible changes in
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the oral mucosa, usually by way of white (leukoplakia)
and red patches (erythroplakia) [2-6]. In addition, there
are other inflammatory disorders of the oral mucosa such
as lichen planus, submucous fibrosis and perhaps oral
fibrosis due to systemic sclerosis that have been associated
with an increased risk of OSCC development [7-10]. It is
believed that identification and monitoring of these
potentially malignant lesions and conditions allows clini-
cians to detect and treat early intraepithelial stages of oral
carcinogenesis, for example mild, moderate or severe dys-
plasia and carcinoma in situ, all of which generally pre-
cede the development of invasive OSCC [2,4,11]. The
prognostic implications of diagnosis and treatment of
these early intra-epithelial stages of oral carcinogenesis are
highly significant due to high survival rates of early OSCC
[11].
The International Agency for Research on Cancer (IARC)
and the World Health Organization (WHO) have recently
stressed that we can reduce a third of a predicted 15 mil-
lion cancer cases in the future and more effectively man-
age another third by planning effective cancer control and
screening strategies [12,13]. The major focus of these strat-
egies is preventable cancers, such as those associated with
tobacco smoking and infection, responsible for 43% of all
cancer deaths in 2000, that is 2.7 million fatalities [2,13].
Oral cancer is among the malignancies that would best
benefit from this approach. It affects an area of the body
that is easy to access for clinical inspection, is preceded by
long-lasting mucosal changes, and has preventable risk
factors [2].
Nevertheless, most OSCC are currently detected at a late
stage (III or IV) [2,4-6,14] and the overall percentage of
oral cancers that are localized when diagnosed is very sim-
ilar to that of colon cancers (36%), even though the
mucosa of the colon requires endoscopic examination for
evaluation [5].
Several studies have attempted to clarify which are the fac-
tors behind the diagnostic delay of OSCC and why figures
concerning prevention and early detection of oral cancer
have remained disappointingly constant over recent dec-
ades. Lack of awareness in the public of the signs, symp-
toms, and risk factors for oral cancer, as well as a
disappointing absence of prevention and early detection
by health-care providers, are both believed to be responsi-
ble for the diagnostic delay [5,14]. For example, at present
time it appears that pelvic examination and Pap smears
are more acceptable than looking in the mouth, a view
shared by both patients and physicians, this culminating
in a significant portion of early oral lesions being missed
by patients and/or health care professionals [15].
In 2005 Sankaranarayanan and co-workers reported the
first solid evidence that periodic examination of the oral
cavity can reduce mortality from oral cancer in high-risk
individuals [16]. Their 9-year screening study reported a
significant 32% reduction in mortality in high-risk indi-
viduals in the intervention group (42% when only male
tobacco/alcohol users are considered), suggesting that
oral visual screening in high-risk patients could prevent
about 40,000 deaths from oral cancer worldwide [16,17].
Further to visual oral examination with the support nor-
mal (incandescent) light, a variety of commercial diagnos-
tic aids and adjunctive techniques have been introduced
[18,19]. These supposedly can assist in the detection of
early cancerous mucosal changes that can be occult to vis-
ual inspection and/or to assess the biologic potential of
clinically abnormal mucosal lesions [18,19]. The latter
aspect is of particular relevance as only a small percentage
of mucosal abnormalities (e.g. potentially malignant dis-
orders) are progressive or become malignant and simple
visual examination cannot discriminate between these
lesions and their non-progressive counterparts. Moreover
effective visual aids would be of great benefit in detecting
a small, but clinically significant, percentage of dysplasias
or early OSCC that are reported to occur within mucosa
that appears clinically normal by visual inspection alone
[20]. There remains, however, little evidence to support
the effectiveness of these adjunctive techniques. The aim
of this paper is to review current evidence regarding avail-
able diagnostic aids of early detection of oral cancer and
provide a critical analysis of their effectiveness.
Brush biopsy
The oral brush biopsy, also known as OralCDx Brush Test
system, consists of a method of collecting a trans-epithe-
lial sample of cells from a mucosal lesion with representa-
tion of the superficial, intermediate and parabasal/basal
layers of the epithelium [21-24]. This test was specifically
designed to investigate mucosal abnormalities that would
otherwise not be subjected to biopsy because of low-risk
clinical features [21-24]. A specially designed brush is the
non-lacerational device used for epithelial cell collection
and samples are eventually fixed onto a glass slide, stained
with a modified Papanicolaou test and analyzed micro-
scopically via a computer-based imaging system. Results
are reported as "positive" or "atypical" when cellular mor-
phology is highly suspicious for epithelial dysplasia or
carcinoma or when abnormal epithelial changes are of
uncertain diagnostic significance respectively. Results are
defined as negative when no abnormalities can be found.
The test is considered an intermediate diagnostic step as a
scalpel biopsy must follow when an abnormal result is
reported (atypical or positive).Head & Neck Oncology 2009, 1:5 http://www.headandneckoncology.org/content/1/1/5
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Several studies have been performed in an attempt to test
the sensitivity and specificity of brush biopsy in detecting
dysplasia or OSCC [21-29]. However, inconsistencies and
potential bias of these studies have been reported by sev-
eral authors [18,27,28]. In the majority of studies for
example, scalpel biopsy was performed after brush biopsy
of lesions with high-risk clinical features, but not after
brush biopsy of innocuously-looking lesions [18]. This is
believed to alter results regarding sensitivity and specifi-
city of the test in the clinical context where accuracy is
much needed (diagnosis of those lesions that appear
innocuous and would otherwise not be biopsied) and
supports the criticism an intermediate non-diagnostic test
would be superfluous when clinical features are highly
suspicious for dysplasia/OSCC and a biopsy has to be per-
formed anyway [18,27,28].
Indeed current data show that OralCDx's cytologic test is
highly sensitive and specific in detecting dysplastic
changes in high-risk mucosal lesions (due to clinical find-
ings suggestive of malignancy), but when used in a low-
risk population with benign-appearing oral epithelial
lesions, the accuracy is reduced and the rate of false-posi-
tive findings increases [18].
Further rigorous studies are needed to investigate the sen-
sitivity and specificity of brush biopsy in detecting in low-
risk populations with clinically innocuous lesions.
Toluidine blue staining
Toluidine blue (TB), also known as tolonium chloride, is
a vital dye that is believed to stain nucleic acids. Hence, it
has been used for many years as an aid to the identifica-
tion of clinically occult mucosal abnormalities and as a
useful way of demarcating the extent of a potentially
malignant lesion prior to excision [30-35]. Several studies
on TB have been performed in the past years but the
majority of them present significant limitations and
methodological biases [18,19]. These have been reviewed
in detail by Lingen and coworkers and include (i) absence
of randomized controlled trials, (ii) absence of histologi-
cal diagnosis as a gold standard, (iii) and variability in
methods of application [18].
Analysis of current evidence suggests that TB is good at
detecting carcinomas, but its sensitivity in detecting dys-
plasias is significantly lower [18]. Furthermore, there
remain a high percentage of false positive stains which
impairs its use in primary care settings as a valid screening
mean [18,19]. In addition, controversy exists regarding
the subjective interpretation of mucosal staining and cri-
teria for positive results (e.g. dark royal blue versus pale
blue staining) [18].
At present, TB is best used by experienced clinicians as an
adjunct to clinical examination in the evaluation of the
biologic potential of potentially malignant oral lesions
[18,19]. A recent study [36] showed that TB preferentially
stained visible lesions with high risk molecular patterns
and predicted risk and outcome in cases where little to no
microscopic evidence of dysplasia was present. To date,
however, research has not been extended to determine
whether TB can identify and predict the risk of progression
for epithelial abnormalities that cannot be seen with the
naked eye [18,19].
Chemiluminescence
Clinical inspection of oral mucosa with the aid of chemi-
luminescent blue/white light was recently suggested to
improve the identification of mucosal abnormalities with
respect to the use of normal incandescent light [18,19,37-
41].
The relevant technology (ViziLite system – Zila Pharma-
ceuticals, Phoenix, AZ), involves the use of an oral rinse
with a 1% acetic acid solution for 1 minute followed by
the examination of the oral mucosa under diffuse chemi-
luminescent blue/white light (wavelength of 490 to 510
nm). The theory behind this technique is that the acetic
acid removes the glycoprotein barrier and slightly desic-
cates the oral mucosa, the abnormal cells of the mucosa
then absorbing and reflecting the blue/white light in a dif-
ferent way with respect to normal cells [18,19,37-41].
Hence normal mucosa appears blue, whereas abnormal
mucosal areas reflect the light (due to higher nuclear/cyto-
plasmic ratio of epithelial cells) and appear more aceto-
white with brighter, sharper and more distinct margins
[37-41].
More recently, the ViziLite system was modified in order
to include the use of TB [42] and a new chemilumines-
cence device (MicroLux DL) was introduced.
Several studies have been performed with the Vizilite sys-
tem with the attempt to demonstrate its efficacy in to
enhance the identification of mucosal abnormalities [37-
42]. It should be highlighted that no study has demon-
strated that the chemiluminescence can help in differenti-
ating dysplasia/carcinoma from benign lesions [18,19].
Hence, the majority of studies have investigated how
chemiluminescence enhances subjective clinical evalua-
tion of intra-oral lesions including brightness, sharpness
and texture with respect to routine clinical examination
[18]. As these parameters are highly subjective, it is not
surprising that results have been contradictory [18,19].
Whilst some authors report that this technique can
improve the detection of intra-oral abnormalities (regard-
less their nature), other reported that the overall detection
rate was not significantly improved and the chemilumi-Head & Neck Oncology 2009, 1:5 http://www.headandneckoncology.org/content/1/1/5
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nescent light produced reflections that made visualization
even more difficult than with incandescent light
[18,19,37-42]. Furthermore, the majority of the studies
are limited by methodological flaws such as lack of his-
topathological diagnosis or clear objectives (screening
device versus case-finding device) [18]. Some studies sug-
gest that chemiluminescence may help identifying occult
lesions that cannot be seen with incandescent light but
this, however, is not supported by any strong evidence
[18,19].
Tissue Fluorescence Imaging
Tissue autofluorescence has been used in the screening
and diagnosis of precancers and early cancer of the lung,
uterine cervix, skin and, more recently, of the oral cavity
[43]. The concept behind tissue autoflorescence is that
changes in the structure (e.g., hyperkeratosis, hyperchro-
matin and increased cellular/nuclear pleomorphism) and
metabolism (e.g. concentration of flavin adenine dinucle-
otide [FAD] and nicotinamide adenine dinucleotide
[NADH]) of the epithelium, as well as changes of the sub-
epithelial stroma (e.g. composition of collagen matrix and
elastin), alter their interaction with light [18,43]. Specifi-
cally, these epithelial and stromal changes can alter the
distribution of tissue fluorophores and as a consequence
the way they emit fluorescence after stimulation with
intense blue excitation (400 to 460 nm) light, a process
defined autoflorescence. The autoflorescence signal is
finally visualized directly by a human observer. With
regards to the oral cavity, normal oral mucosa emits a pale
green autofluorescence when viewed through the instru-
ment handpiece whilst abnormal tissue exhibits
decreased autofluorescence and appears darker with
respect to the surrounding healthy tissue. Autoflorescence
technology for inspection of the oral mucosa has been
developed by LED Medical Diagnostics Inc. in partnership
with the British Columbia Cancer Agency and is marketed
as VELscope system [18,19,43].
Several studies have investigated the effectiveness of the
VELscope system as an adjunct to visual examination for
(i) improving the distinction between between normal
and abnormal tissues (both benign and malignant malig-
nant changes), (ii) differentiating between benign and
dysplatic/malignant changes, (iii) and identifying dys-
plastic/malignant lesions (or lesion's margins) that are
not visible to the naked eye under white light [18,19,43-
46]. Overall the quality of available studies is significantly
higher than that of studies upon chemiluminescence and
TB as the technology's sensitivity and specificity was com-
pared to gold standard (histopathology) in all patients
studied [18,19,43-46]. With regard to the first aspect,
autofluorescence imaging of the oral mucosa has been
reported to possibly improve lesions' contrast and there-
fore increase the ability to distinguish between mucosal
lesions and healthy mucosa, although further research on
different patients population is needed [43]. The ability of
autofluorescence to differentiate between different lesion
types has been investigated in a few studies and overall the
technique seems to show high sensitivity, but low specifi-
city [43]. However, the VELscope system seems to be very
promising due to its ability and effectiveness in identify-
ing lesions and lesions' margins that are occult to visual
examination under white light [18,19,43-46]. Using his-
tology as the gold standard, VELscope demonstrated high
sensitivity and specificity in identifying areas of dysplasia
and cancers that extended beyond the clinically evident
tumors [18,19,43-46]. A direct clinical application con-
sists of assessing lesion margins in patients with poten-
tially malignant oral disorders therefore improving
surgical management [47,48].
However, it should be highlighted that these results are
from case series and case reports rather than clinical trials
and that no published studies have assessed the VELscope
system as a diagnostic adjunct in screening lower-risk
populations (e.g. without a history of dysplasia/OSCC) or
in patients seen by primary care providers [18,19,43-48].
Tissue Fluorescence Spectroscopy
In addition to visual autofluorescence, a technique called
autofluorescence spectroscopy has been recently tested in
oral oncology research [18,19,43,49]. The autofluores-
cence spectroscopy system consists of a small optical fiber
that produces various excitation wavelengths and a spec-
trograph that receives and records on a computer and ana-
lyzes, via a dedicated software, the spectra of reflected
fluorescence from the tissue [18,19,43,49]. This technique
has the clear advantage of eliminating the subjective inter-
pretation of tissue fluorescence changes. However, the
downside is that more variables (e.g. combination of
wavelengths, methodology of fluorescence analysis etc)
have to be tested and considered and this has led to con-
troversial and often unclear results [18,19,43,49]. Overall,
autofluorescence spectroscopy seems to be very accurate
for distinguishing lesions from healthy oral mucosa, with
high sensitivity and specificity, especially when malignant
tumors are compared to healthy mucosa. However, the
ability of the technique to distinguish and classify differ-
ent types of lesion has been reported to be low
[18,19,43,49]. Moreover autofluorescence spectroscopy is
for practical reasons not suitable to detect new lesions or
to demarcate large lesions as the optical fiber can sample
only a small mucosal area [18,19,43,49]. This limits the
use of spectroscopy to the evaluation of a well defined
small mucosal lesion that has been already identified
through visual inspection, with the attempt to clarify its
benign or (pre)malignant nature. Further research is
needed to support this clinical application of autofluores-
cence spectroscopy.Head & Neck Oncology 2009, 1:5 http://www.headandneckoncology.org/content/1/1/5
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Conclusion
The World Health Organization has clearly indentified
prevention and early detection as the major targets in the
battle to control the oral cancer burden worldwide [2,50].
Prevention and early detection of OSCC and its pre-inva-
sive intra-epithelial stages is still largely based on visual
examination of the mouth, although a variety of molecu-
lar techniques have been tested and are likely to represent
the ultimate goal of oral cancer research [51]. A 9-year ran-
domized controlled trial has shown that screening via vis-
ual examination of the oral mucosa under white light is
effective in reducing mortality in individuals exposed to
risk factors. Simple visual examination, however, is well
known to be limited by subjective interpretation and by
the potential, albeit rare, occurrence of dysplasia and early
OSCC within areas of normal-looking oral mucosa. As a
consequence, adjunctive techniques have been suggested
to increase our ability to differentiate between benign
abnormalities and dysplastic/malignant changes as well
as identify areas of dysplasia/early OSCC that are not vis-
ible to naked eye. Chemiluminescence and autofluores-
cence are two relatively new techniques that have been
investigated with variable results. Available studies have
shown promising results, but strong clear evidence to sup-
port their effectiveness is still lacking. Major limitations
include analysis of small sample sizes, lack of methodo-
logically sound clinical trials, insufficient use of histologic
and molecular mapping of optically altered mucosa, need
of more detailed analysis of factors rather than cancer that
can affect the optical qualities of the oral mucosa (e.g.
inflammation, previous chemo- or radio-therapy), and
also direct comparison with other detection methods.
Toluidine Blue has been used by clinicians for many years,
yet a clear demonstration of TB indications, limitations, as
well as strong evidence from methodologically sound
clinical trials is still lacking. Brush biopsy is another exam-
ple of promising novel diagnostic technique that unfortu-
nately has not been supported by robust evidence.
Clinical trials have been performed but in the majority of
cases results should be read with caution due to biases,
variations in research objectives and methodological
inconsistencies.
At present, the utilization of these techniques in clinical
practice is largely anedoctal and is principally directed to
help experienced clinicians at improving their ability to
detect dysplasia and early OSCC in high-risk individuals
attending secondary and tertiary centers. Moreover, expe-
rienced surgeons use some of the described optic aids to
improve the identification of a lesion's margins and exten-
sions in the operatory setting, although it is not know
then impact these techniques have on a patient's survival
and risk of disease recurrence.
Further research with clear objectives, well-defined popu-
lation cohorts and sound methodology is required before
supporting the extensive use of oral cancer diagnostic aids
in both primary and specialty settings.
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